The cost of drugs in 2019 amounted to 7.6 billion francs, stabilizing compared to 2018, says insurer Heslana in its report on drugs. The use of biosimilars remains underexploited despite the significant savings potential that these drugs present.
After several years of continuous increases, the cost of drugs stabilized to reach 7.6 billion francs last year. This phenomenon is explained by price controls by the Federal Office of Public Health and the expiration of patents for certain expensive drugs.
Read also : Health: more than 300 drugs see their prices drop
This price stability does not mean a trend reversal, qualifies a press release Wednesday from Helsana. New, expensive drugs are rapidly driving up costs.
The cancer / immunological drug groups are the most expensive: per head, their costs exceeded 9,000 francs per person. Next come those for the nervous system and metabolic preparations.
Underutilized biosimilars
The use of biosimilar drugs would save money. In 2019, if the latter had completely replaced their biological counterparts, the savings potential would have amounted to 60 million francs, estimates the Helsana report, which regrets that the market in Switzerland in this area is still not very dynamic.
Helsana also analyzed the medication of vulnerable patients receiving home help and care. Since 2013, medication use has increased by more than 47%. On average, they take sixteen drugs in parallel, compared to nine for residents of nursing homes.
These were the details of the news the price of medicines has … for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at en24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
